Patents by Inventor Ravichandran Ramasamy
Ravichandran Ramasamy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11730737Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: GrantFiled: May 28, 2020Date of Patent: August 22, 2023Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew Wasmuth, Donald W. Landry, Shixian Deng, Banavara L. Mylari, Ravichandran Ramasamy, Ann Marie Schmidt
-
Patent number: 11529349Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: GrantFiled: October 10, 2019Date of Patent: December 20, 2022Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew Wasmuth, Donald W. Landry, Shixian Deng, Banavara L. Mylari, Ravichandran Ramasamy, Ann Marie Schmidt
-
Publication number: 20220296604Abstract: Indole compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, schemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.Type: ApplicationFiled: August 5, 2020Publication date: September 22, 2022Applicants: NEW YORK UNIVERSITY, UNIVERSITY OF ALBANYInventors: Ann Marie SCHMIDT, Ravichandran RAMASAMY, Alexander SHEKHTMAN, Vivek RAI, Michaele B. MANIGRASSO
-
Patent number: 11192859Abstract: Quinoline compounds are disclosed that have a formula represented by the following: and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.Type: GrantFiled: April 18, 2017Date of Patent: December 7, 2021Inventors: Ann Marie Schmidt, Ravichandran Ramasamy, Alexander Shekhtman, Vivek Rai, Michaele B. Manigrasso
-
Patent number: 11076593Abstract: It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2.Type: GrantFiled: August 27, 2018Date of Patent: August 3, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard J. Deckelbaum, Ravichandran Ramasamy
-
Publication number: 20200289512Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: ApplicationFiled: May 28, 2020Publication date: September 17, 2020Inventors: Andrew WASMUTH, Donald W. LANDRY, Shixian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
-
Publication number: 20200268755Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: ApplicationFiled: October 10, 2019Publication date: August 27, 2020Inventors: Andrew WASMUTH, Donald W. LANDRY, Shixian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
-
Patent number: 10729695Abstract: Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.Type: GrantFiled: April 15, 2019Date of Patent: August 4, 2020Assignees: The Research Foundation for the State University of New York, New York UniversityInventors: Ann Marie Schmidt, Ravichandran Ramasamy, Alexander Shekhtman, Vivek Rai, Michaele B. Manigrasso
-
Patent number: 10639306Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: GrantFiled: March 5, 2019Date of Patent: May 5, 2020Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Andrew Wasmuth, Donald W. Landry, Shixian Deng, Banavara L. Mylari, Ravichandran Ramasamy, Ann Marie Schmidt
-
Publication number: 20190374548Abstract: Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.Type: ApplicationFiled: April 15, 2019Publication date: December 12, 2019Inventors: Ann Marie Schmidt, Ravichandran Ramasamy, Alexander Shekhtman, Vivek Rai, Michaele B. Manigrasso
-
Publication number: 20190201400Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: ApplicationFiled: March 5, 2019Publication date: July 4, 2019Inventors: Andrew WASMUTH, Donald W. LANDRY, Shi Xian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
-
Publication number: 20190194136Abstract: Quinoline compounds are disclosed that have a formula represented by the following: and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.Type: ApplicationFiled: April 18, 2017Publication date: June 27, 2019Inventors: Ann Marie SCHMIDT, Ravichandran RAMASAMY, Alexander SHEKHTMAN, Vivek RAI, Michaele B. MANIGRASSO
-
Patent number: 10265320Abstract: Amino, amido, and heterocyclic compounds are disclosed. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.Type: GrantFiled: May 25, 2016Date of Patent: April 23, 2019Assignees: The Research Foundation for The State University of New York, New York UniversirtyInventors: Ann Marie Schmidt, Ravichandran Ramasamy, Alexander Shekhtman, Vivek Rai, Michaele B. Manigrasso
-
Publication number: 20190000072Abstract: It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2.Type: ApplicationFiled: August 27, 2018Publication date: January 3, 2019Inventors: Richard J. Deckelbaum, Ravichandran Ramasamy
-
Publication number: 20180271865Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: ApplicationFiled: May 25, 2018Publication date: September 27, 2018Inventors: Andrew WASMUTH, Donald W. LANDRY, Shixian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
-
Patent number: 10070643Abstract: It has been discovered that isolated organs and tissues perfused/reperfused in perfusion buffer to which omega-3 glyceride oil had been added retain higher levels of function than if perfused/reperfused without the omega-3 glycerides. Isolated hearts reperfused ex vivo after induced ischemia in n-3 triglyceride perfusion emulsion maintained a normal heart rate and normal LVDP and showed a dramatically reduced frequency of arrhythmias compared to control hearts. Further, test hearts reperfused with n-3 oil triglyceride emulsion showed a decrease in creatine kinase and upregulation of certain beneficial proteins including the anti-apoptotic gene marker Bcl-2.Type: GrantFiled: March 28, 2014Date of Patent: September 11, 2018Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard J. Deckelbaum, Ravichandran Ramasamy
-
Patent number: 10052324Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: GrantFiled: July 27, 2017Date of Patent: August 21, 2018Assignee: The Trustees of Columbia University in the City of New YorkInventors: Andrew Wasmuth, Donald W. Landry, Shi Xian Deng, Banavara L. Mylari, Ravichandran Ramasamy, Ann Marie Schmidt
-
Publication number: 20180110770Abstract: The present invention is directed to ferroptosis and glutaminolysis inhibitors and to methods of treatment or prevention of an organ injury caused by ischemia-reperfusion in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a ferroptosis inhibitor or a glutaminolysis inhibitor.Type: ApplicationFiled: November 22, 2017Publication date: April 26, 2018Inventors: Minghui GAO, Ravichandran RAMASAMY, Xuejun JIANG
-
Publication number: 20170319584Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: ApplicationFiled: July 27, 2017Publication date: November 9, 2017Inventors: Andrew WASMUTH, Donald W. LANDRY, Shi Xian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT
-
Publication number: 20170216292Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.Type: ApplicationFiled: April 18, 2017Publication date: August 3, 2017Inventors: Andrew WASMUTH, Donald W. LANDRY, Shixian DENG, Banavara L. MYLARI, Ravichandran RAMASAMY, Ann Marie SCHMIDT